History of stroke or transient ischemic attack
Subjects with prior history of myocardial infarction, transient ischemic attack, or stroke in the last  months
History of arterial thrombosis (eg, stroke or transient ischemic attack) within  months of first dose of AMG 
History of arterial thrombosis (eg, stroke or transient ischemic attack) in the past  months.
History of stroke or transient ischemic attack within the previous  months
History of stroke, reversible ischemic neurological defect, or transient ischemic attack within  months prior to Day 
History of stroke, reversible ischemic neurological defect, or transient ischemic attack within  months prior to initiation of study treatment
History of stroke or transient ischemic attack within  months prior to registration
History of arterial thrombosis (eg, stroke or transient ischemic attack) in the past  months Infection requiring intravenous antibiotics within  week of study enrollment (day )
History of stroke or transient ischemic attack within  months prior to day 
History of arterial thrombosis (eg, stroke or transient ischemic attack) within  months of enrollment.
History of stroke or transient ischemic attack within  months of the randomization
History of stroke, reversible ischemic neurological defect, or transient ischemic attack within  months prior to Day 
Symptomatic carotid artery disease, as manifested by a recent transient ischemic attack (within  days), ischemic stroke, or amaurosis fugax (monocular visual ischemic symptoms or blindness).
Cerebrovascular disease manifested as prior stroke at any time or transient ischemic attack (TIA) in the  months prior to initiation of therapy
History of stroke or transient ischemic attack within  months prior to registration
PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: History of stroke, transient ischemic attack (TIA), or myocardial infarction, within  months prior to CD
History of stroke or transient ischemic attack within  months prior to cycle , day 
Cerebrovascular event (transient ischemic attack, stroke or CNS bleeding) within the last  months.
History of stroke or transient ischemic attack within six months
History of stroke or transient ischemic attack within  months prior to study enrollment
History of stroke or transient ischemic attack within  months prior to day 
History of transient ischemic attack (TIA) or stroke within  months of study entry
Stroke within  months of screening, or transient ischaemic attack (TIA) within  months of screening
 History of arterial thrombosis (eg, stroke or transient ischemic attack) within  months of first dose of AMG .
History of transient ischemic attack within the previous  months
History of stroke or transient ischemic attack =<  months prior to registration
History of stroke or transient ischemic attack within six months
History of stroke or transient ischemic attack within  months prior to Day
History of stroke or transient ischemic attack within  months prior to study enrollment
History of stroke or transient ischemic attacks within  months prior to study enrolment.
Patients are excluded if they have a history of stroke or transient ischemic attack within  months prior to randomization
History of stroke or transient ischemic attack within  months prior to cycle , day 
History of stroke or transient ischemic attack within  months
History of stroke or transient ischemic attack within  months prior to beginning treatment.
History of stroke or transient ischemic attack, or other arterial thrombosis =<  months prior to randomization
Participants may not have had a history of a stroke or transient ischemic attack within six months
Patients must have not have a history of hemorrhagic or ischemic stroke, including transient ischemic attacks and other central nervous system bleeding in the preceding  months that were not related to glioma surgery
Stroke or transient ischemic attack
Myocardial infarction and transient ischemic attack or stroke within  months prior to enrollment
History of a stroke or transient ischemic attack within  months
-  History of stroke or transient ischemic attack within  months prior to Day .
History of stroke or transient ischemic attack within  months prior to day 
Clinical significant uncontrolled conditions \ active infection, myocardial infarction, stroke, or transient ischemic attack, psychiatric illness/social situations that would limit compliance.
Prior history of stroke or transient ischemic attack within  months prior to day -
History of myocardial infarction, unstable angina, stroke, or transient ischemic attack within  months prior to day 
Patients with a history of myocardial infarction, unstable angina, stroke, or transient ischemic attack (TIA) within  months prior to planned day  of dosing are ineligible
History of stroke or transient ischemic attack
History of stroke or transient ischemic attack within six months
History of stroke or transient ischemic attack (TIA) within  months prior to Cycle , Day 
History of stroke or transient ischemic attack within  months prior to Day 
Past history of stroke or transient ischemic attack requiring medical therapy
Symptomatic peripheral vascular disease, stroke or transient ischemic attack within  months
Patients with either of the following within  months before the first dose of study treatment:\r\n* Stroke (including transient ischemic attack [TIA], or other ischemic event)\r\n* Myocardial infarction
History of stroke or transient ischemic attack within  months prior to registration
History of stroke or transient ischemic attack within  months prior to beginning treatment.
History of stroke or transient ischemic attack within  months prior to study enrollment
History of stroke or transient ischemic attack within  months prior to day 
History of stroke or transient ischemic attack within  months of first study dose
No history of stroke or transient ischemic attack
History of stroke, reversible ischemic neurological defect or transient ischemic attack within  months prior to Day 
History of cardiovascular disease including prior myocardial infarction, angina, stroke, or transient ischemic attack (TIA)
History of progressive promyelocytic leukemia (PML), known history of pancreatitis, active grade  or higher viral, bacterial or fungal infection =<  weeks prior to registration and documented history of cerebrovascular event (stroke or transient ischemic attack [TIA]) =<  months prior to registration
Stroke or transient ischemic attack within  months of screening
History of stroke or transient ischemic attack in the preceding  months
History of stroke/transient ischemic attack
